Structure Therapeutics Inc. Expected to Earn FY2024 Earnings of ($1.10) Per Share (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ:GPCR) – Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Structure Therapeutics in a research note issued to investors on Tuesday, April 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($1.10) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $65.00 price objective on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.96) per share.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04.

Separately, Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $85.71.

Structure Therapeutics Stock Down 2.3 %

Shares of NASDAQ:GPCR opened at $39.32 on Friday. Structure Therapeutics has a twelve month low of $21.79 and a twelve month high of $75.02. The stock’s 50 day moving average is $41.52 and its 200-day moving average is $48.68. The firm has a market capitalization of $1.83 billion and a price-to-earnings ratio of -47.37.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in GPCR. Adage Capital Partners GP L.L.C. increased its holdings in Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after acquiring an additional 1,607,525 shares during the last quarter. Wellington Management Group LLP grew its holdings in Structure Therapeutics by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 867,579 shares of the company’s stock valued at $43,743,000 after buying an additional 657,310 shares in the last quarter. FMR LLC grew its holdings in Structure Therapeutics by 28.5% during the 3rd quarter. FMR LLC now owns 1,590,335 shares of the company’s stock valued at $80,185,000 after buying an additional 352,600 shares in the last quarter. TD Asset Management Inc grew its holdings in Structure Therapeutics by 109.3% during the 3rd quarter. TD Asset Management Inc now owns 152,176 shares of the company’s stock valued at $7,673,000 after buying an additional 79,467 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Structure Therapeutics during the 3rd quarter valued at about $7,611,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.